PO.TB10.13 · 肿瘤生物学
II期结肠癌中与PNI和LVI相关的空间生物标志物
Spatial biomarker related to PNI and LVI in stage II colon cancers
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
多项回顾性研究和荟萃分析显示,淋巴血管浸润(LVI)和/或神经周围浸润(PNI)的存在与II期结直肠癌(CRC)显著更差的无病生存和总生存相关,这些特征在决定是否推荐II期疾病辅助化疗时常被考虑。本研究回顾了32例II期CRC患者存档的FFPE样本,以研究LVI、PNI或无浸润组间的免疫细胞特征。使用PN 7-Plex检测试剂盒(PhenoVision Bio Co., ltd)进行IHC对照、多重免疫荧光(mIF)板对照及随后的mIF染色,分别靶向CD68、CD3、CD20、panCK、PD-1、PD-L1和CD68、panCK、CD3、CD8、CD163、alphaSMA。QC程序确保mIF结果中每个标志物与IHC染色中同一标志物呈现相同的位置和密度。扫描64张染色切片,由病理学家基于每个样本连续切片的H&E染色勾画肿瘤区域。利用从Oncotopix Discovery系统(Visiopharm)训练的PhenoVision mIF AI分析系统分析非肿瘤区、肿瘤浸润边缘(IM,定义为肿瘤边界内外各360μm即总共720μm)、肿瘤实质、肿瘤基质、肿瘤实质边界内外30μm区域。分析阳性细胞百分比以供进一步分析。统计分析显示,基于二元逻辑回归,肿瘤浸润区CD20和CD20+/PD-1-细胞百分比与PNI状态相关(p = 0.046和0.046),肿瘤实质外30μm的CD68+/CD163-细胞百分比与PNI相关(p = 0.048)。在肿瘤浸润区,PNI组相较于非PNI组有更高的CD20+阳性细胞百分比和CD20+/PD-1-细胞百分比(p = 0.013和0.013)。而在肿瘤实质外30μm区域,PNI组相较于非PNI组观察到更低的CD68+CD163-细胞百分比(p = 0.01)。在肿瘤实质区,LVI阳性组相较于非LVI组有显著更多的panCK细胞百分比(p = 0.000)。本研究表明,空间生物标志物在II期结肠癌的肿瘤浸润边缘和肿瘤实质区与PNI和LVI相关,这可能与II期CRC预后相关。计划增加样本数量以进行空间标志物分布特征与疾病预后的分析。
查看英文原文 English abstract
Multiple retrospective studies and meta-analyses have shown that presence of lymphovascular invasion (LVI) and/or perineural invasion (PNI) is associated with significantly worse disease-free and overall survival in stage II colorectal cancer (CRC), and these features are commonly considered when deciding whether to recommend adjuvant chemotherapy for stage II disease. Current study reviewed 32 stage II CRC patient archived FFPE samples to investigate immune cell features among LVI, PNI or no-invasion groups. IHC control, multiplex immunofluorescence (mIF) panel control and the followed mIF staining were conducted using PN 7-Plex Detection Kit (PhenoVision Bio Co., Itd) targeted CD68, CD3, CD20, panCK, PD-1, PD-L1 and CD68, panCK, CD3, CD8, CD163, alphaSMA, respectively. The QC procedures made sure each marker from mIF results exhibited identical location and density of the same marker from IHC staining. The 64 staining slides were scanned, tumor areas were lined out by pathologist based on H&E staining from the serial section of each sample. Non-tumor region, tumor invasive margin (IM) , which was defined as 360μm within and outside of tumor boundary i.e. total 720μm, tumor parenchyma, tumor stromal, 30μm region inside and outside of tumor parenchyma boundary were analyzed using PhenoVision mIF AI analysis system trained from Oncotopix Discovery system (Visiopharm). Positive cell percentage were analyzed for further analysis. Statistical analysis exhibited correlation of CD20 and CD20+/PD-1- cell percentage to PNI condition ( p =0.046 and 0.046, respectively) in tumor invasive region and CD68+/CD163- cell percentage to PNI ( p =0.048) of 30μm outside tumor parenchyma based on binary logistic regression. There were higher CD20+ positive cell percentage and CD20+/PD-1- cell percentage in PNI group vs. non PNI group ( p =0.013 and 0.013, respectively) at tumor invasive region. Whereas lower CD68+CD163- cell percentage was observed in PNI group vs. non PNI group of 30μm outside of tumor parenchyma region ( p =0.01). There was significant more panCK cell percentage in LVI positive group at tumor parenchyma region compared to non LVI group ( p =0.000). Current study indicates that spatial biomarkers are correlated to PNI and LVI in tumor invasive margin and tumor parenchyma region of stage II colon cancers which may be related to stage II CRC prognosis. Increased sample number of the spatial marker distribution feature to disease prognosis analysis are scheduled.
利益披露 Disclosure
H. Hu, None.
H. Sun,
Beijing PhenoVision Bio Co., ltd Employment.
L. Zhu,
Beijing PhenoVision Bio Co., ltd Employment.
S. Han,
Beijing PhenoVision Bio Co., ltd Employment.
Z. Zhang,
Beijing PhenoVision Bio Co., ltd Employment.
E. Zhang,
Hangzhou PhenoVision Bio Co., Itd Employment.
N. Li,
Hangzhou PhenoVision Bio Co., Itd Employment.
Beijing PhenoVision Bio Co., Itd Employment.
G. Wang, None.